Startup profile · funding coverage
Knownwell funding, valuation and investors
Weight-inclusive primary and metabolic health clinics—hybrid virtual plus in-person obesity care.
Keep track of Knownwell
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Strategic
$25M · October 2025
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$45M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Boston, Massachusetts
Overview
Knownwell (knownwell.co) operates weight-inclusive primary care and metabolic health clinics combining in-person visits with virtual coaching, nutrition, behavioral health, and medication management. The company raised a $20 million Series A in December 2023 led by a16z Bio + Health with Flare Capital Partners per Business Wire. In October 2025, CVS Health Ventures led a $25 million strategic investment with a16z re-upping per MobiHealthNews—signaling payer and retail interest in comprehensive obesity care beyond single-drug telehealth plays. Knownwell emphasizes stigma-free, long-term metabolic health rather than short-term weight-loss marketing.
Why Knownwell is interesting
Knownwell builds longitudinal obesity medicine beyond GLP-1-only telehealth; a16z Bio led $20M Series A and CVS Health Ventures led a $25M strategic round as retail health bets on comprehensive metabolic care.
Product & use cases
Knownwell delivers hybrid obesity and metabolic clinics—primary care, coaching, labs, and GLP-1 or other therapies when appropriate—under a weight-inclusive clinical model.
- Longitudinal obesity and metabolic syndrome management
- Employer and health-plan metabolic health programs
- Hybrid care combining in-clinic and virtual touchpoints
Key facts
- Series A (Dec 2023): $20M led by a16z Bio + Health (Business Wire)
- Strategic (Oct 2025): $25M led by CVS Health Ventures; a16z re-upped (MobiHealthNews)
- Weight-inclusive primary and metabolic obesity care model
- Hybrid in-person plus virtual clinic footprint expanding
Funding history (newest first)
Strategic
2025-10 $25M- CVS Health Ventures (lead)
- Andreessen Horowitz (participant)
Source: https://www.mobihealthnews.com/news/knownwell-raises-25m-cvs-health-ventures
Series A
2023-12 $20M- Andreessen Horowitz (lead)
- Flare Capital Partners (participant)
Investors in our directory
Funds linked from Knownwell's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Full-stack clinic model with explicit weight-inclusive positioning—broader than GLP-1 prescription mills that dominated 2023–2024 telehealth hype.
GLP-1 availability commoditized medication access; Knownwell bets integrated primary care and coaching differentiate on outcomes and retention. CVS strategic capital helps distribution but raises questions about independence vs retail clinic integration.
-
Calibrate / Found direct
Metabolic telehealth brands; varying clinic vs virtual-only depth.
-
Omada Health adjacent
Digital chronic disease programs; employer channel overlap.
-
Traditional primary care incumbent
PCPs often lack dedicated obesity medicine infrastructure.
Notable stories
- CVS Health Ventures strategic round ties Knownwell to retail pharmacy distribution narrative (MobiHealthNews).
- Company launched amid GLP-1 boom but emphasizes whole-person metabolic care—not drugs alone.
- a16z Bio + Health led Series A as obesity category attracted renewed venture attention post-2022.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Knownwell's financing or category context.
FAQs about Knownwell
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.